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SUNCT and high nocturnal prolactin levels:
some new unusual characteristics






Abstract SUNCT is a rare condi-
tion characterised by a short-last-
ing periorbital pain associated with
autonomic symptoms and is usual-
ly unresponsive to pharmacologi-
cal treatment. We report a case of
SUNCT syndrome linked to a pitu-
itary micro-adenoma, with only
nocturnal attacks. The nocturnal
levels of prolactin (PRL) were
increased, while other hormonal,
haematological, serological and
biochemical investigations and
levels of PRL did not reveal abnor-
mal findings during the day-time.
PRL serum secretion after thy-
rotropin-releasing hormone test
was lower than nocturnal secre-
tion, but not enough to induce
severe attacks. We suggest that in
our patient the rise of nocturnal
levels of PRL could have a direct
role in the worsening of this
headache, perhaps secondarily to
an altered regulation of the hypo-
thalamic–hypophysial axis, 
however the actual influence of
sleep and the interaction between
all neurotransmitters and hormones
needs to be clarified further.
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Recurrent short-lasting unilateral neuralgiform headache
attacks with conjunctival injection and tearing (SUNCT)
were first described by Sjaastad et al. in 1978 as a distinct
and rare clinical entity [1]. The typical form is charac-
terised by several attacks of moderate or severe orbital,
periorbital or temporal, stabbing or pulsating pain lasting
5–250 s, with ipsilateral conjuctival injection, lacrimation
and rhinorrhoea or nasal obstruction. An irregular tempo-
ral pattern is the rule, with symptomatic periods alternat-
ing with remissions in an unpredictable fashion. During
active periods, the frequency of attacks may vary from <1
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attack/day to >30 attacks/hour [2]. The attacks predomi-
nate during the daytime, nocturnal attacks being seldom
reported [3]. The pathophysiology of this headache form
is still unknown [4], though functional magnetic reso-
nance imaging (fMRI) studies in spontaneous attacks have
demonstrated activation of the ipsilateral hypothalamic
grey [5]. We described a new case linked to adenoma pitu-
itary gland with some unusual characteristics which will
extend our knowledge of the full spectrum of this disease.
Case report
A 32-year-old woman was admitted to our observation in
April 2004 because of recurrent short attacks of severe
ocular and periocular pain. Her short-lasting pain episodes
had started about two years earlier (April–May, 2002),
were strictly on the right side, accompanied by ipsilateral
conjuctival injection, tearing and nasal congestion. Her
personal history had been positive for oligo-amenorrhoea
for about three years. The characteristic of the present
case was that headache attacks always occurred during
sleeping hours, approximately between 2:00 and 5:00
a.m.. Occasionally a pain-free period of 3–4 months was
reported. Duration of the headaches was 30–100 s, with
frequency raging from 10–20 attacks per night, interfering
with sleep and with quality of life. The general and neu-
rological examination was normal. Cranial and sella-turci-
ca magnetic resonance imaging (MRI) with gadolinium
showed a pituitary gland micro-adenoma (Fig. 1). The
polysomnographic studies, recorded during nocturnal
episodes, did not show any abnormality. The diurnal
rhythmicity secretion of serum prolactin (PRL), luteinis-
ing hormone (LH), follicle-stimulating hormone (FSH),
oestradiol, progesterone, T3, T4, thyrotropin (TSH) and
TSH response to thyrotropin-releasing hormone (TRH)
test were studied for two consecutive days during active
headache period (Table 1a). The patient was admitted to
the hospital in the early morning on the 1st day of the
study. At least 1 h before the first blood sampling an
indwelling catheter was inserted into an antecubital vein.
The blood samples at night were drawn in dim light.
Blood samples were drawn every 1 h in the 24 h for two
consecutive days. The patient was asked to take notes in a
diary on time and duration of attacks. The same valuations
were effected for two consecutive days two months later,
during clinical remission period (Table 1b). The hormon-
al, haematological, serological and biochemical investiga-
tions did not reveal abnormal findings during the day-
time; otherwise only in the symptomatic nocturnal period
were headache attacks often associated with increased
serum PRL levels (Fig. 2). PRL responses increased after
TRH test, but did not induce severe attacks. Nocturnal
PRL level was higher than maximum values after TRH
test, and no significant differences between active period
and remission were observed. The patient was given
cabergoline 0.5 mg/week. The dopamine-agonist dose was
Table 1 Levels of PRL at 8 a.m. and after 1, 2, 3, 4 hours in basal condition and after TRH-test and at 1 a.m. after 1,2, 3, 4 hours during
symptomatic (a) and remission periods (b).
(a) Symptomatic periods
Diurnal secretion Time (h) 8 9 10 11 12
Value (ng/mL) 18±1.2 15±0.9 15±1.1 12±0.6 18±0.7
After TRH test Time 8 9 10 11 12
Value 42±2.7 46±2.2 48±1.2 34±1.7 36±1.8
Nocturnal secretion Time 1 2 3 4 5
Value 70±2.2 82±2.2 98±2.8 87±2.3 65±1.2
(b) Remission periods
Diurnal secretion Time (h) 8 9 10 11 12
Value (ng/mL) 14±1.3 15±1.1 12±1.1 10±0.9 12±0.2
After TRH test Time 8 9 10 11 12
Value 50±2.6 44±2 46±1.1 42±1.4 32±1.4
Nocturnal secretion Time 1 2 3 4 5
Value 22±0.9 34±1.2 26±1.2 28±1.3 16±0.5
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thereafter elevated to 1 mg/week. The headaches were
resolved completely within 4 months.
Discussion
Among the neuro-endocrinological alterations, disorders
of the hypothalamic–hypophysial axis are believed to be
implicated in the pathogenesis of several headache syn-
dromes [6]. PRL was first measured in patients already
suffering from chronic headaches. Here we present a
woman with SUNCT linked to pituitary micro-adenoma,
who was found to have increased nocturnal levels of PRL.
We found that the rise of serum PRL during attacks was
not accompanied by a TSH rise. This case, along with
other similar reports in the literature, supports the hypo-
thalamic connection to this trigeminal autonomic cepha-
lalgia [7]. The pathophysiology of SUNCT is unknown,
though fMRI studies in attacks have documented activa-
tion of the ipsilateral hypothalamic grey [5]. Some authors
suggest a hypersensitivity of dopamine receptors based on
the observation that some headaches showed higher PRL
after taking dopaminergic agents [8]. Reduced respon-
siveness of pituitary lactotroph cells to the action of
dopaminergic agents has also been postulated [9]. Other
authors suggested a serotoninergic hyperfunction rather
than dopaminergic dysfunction. Serotonin is known to
increase PRL secretion and decrease TSH secretion [10].
Therefore, dopaminergic hypofunction could be the con-
sequence of serotoninergic hyperfunction, because of the
inhibitory effect of serotonin on dopamine neurons. In
fact, in patients with SUNCT the treatment with
dopamine-agonists can determine various responses, with
worsening in some cases [7] and improvement in others
[11, 12]. Most cases of SUNCT syndrome are primary but
several cases of SUNCT are secondary and occur in
patients with pituitary tumours, further supporting
involvement of the hypothalamic–hypophysial axis. There
are seven cases reported of SUNCT syndrome secondary
to pituitary adenomas in the medical literature, of which
four cases had prolactinomas [10–12], two non-secreting
macro-adenoma [13, 14] and one case had micro-adenoma
linked to acromegaly [15]. In all the case reports with pro-
lactinoma, the tumour was ipsilateral to the side of the
attacks, producing a possible mass effect or mechanical
mode of action, which may have played a role in SUNCT
onset. Nevertheless, even if a mechanical mode may be a
plausible mechanism for the headache in the cases of pitu-
itary macro-adenomas and cavernous sinus invasion, it is
not an acceptable explanation for the attacks in micro-ade-
nomas.
A few studies reported how patients with micro-adeno-
ma may suffer from severe headache, while patients with
macro-adenoma may not have headache. This suggests
that mass effect of the tumour is not correlated to the pres-
ence or intensity of the headache [11], but rather the
headache syndromes may result from alterations in the
neuro-endocrine system. Recently, in the case reported by
Rozen, the complete cessation of headaches after the
Fig. 1 MRI scan with contrast of the brain showing a micro-ade-
noma pituitary gland
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removal of an acromegalic micro-adenoma was docu-
mented, suggesting a potential role also for GH in SUNCT
pathogenesis [15]. Indeed, the neuro-endocrine mecha-
nism could be an important factor in triggering and abort-
ing headaches, supported by the result of studies regard-
ing the analgesic effect of somatostatin analogues [16].
Moreover, a study documented low levels of serum testos-
terone in a case of SUNCT, in which clomiphene citrate
therapy induced a significant rise of testosterone values
and led to a remarkable decrease of the SUNCT attacks
[17].
In the present case, as the tumour was located in the
pituitary left side while the pain affected the right side and
in view of the relatively small size of lesion, a mechanical
origin for headaches is not plausible [18], so the neuro-
humoral mechanism influence can be suggested. The
mean observed values of the nocturnal serum PRL, evalu-
ated on two consecutive days, were significantly higher
during the symptomatic period and lower during remis-
sion phases. It is supposed that prolactinomas have abnor-
mal secretory behaviour associated with lactotrope neo-
plastic transformation and/or isolation of tumour cell mass
from normal hypothalamic controls, with a consequent
irregular PRL secretion pattern [19, 20]. Nocturnal attacks
have been described in patients with SUNCT [3], never-
theless attacks exclusively during the night-time are an
unusual expression, never before described in other
papers. Basal serum levels of LH, FSH, progesterone,
oestradiol, cortisol, ACTH, GH, T3, T4, TSH and TRH
test were normal and there were no difference between
active and remission period. Moreover, excluding amen-
orrhoea, there were no documented clinical signs related
to other endocrine disorders. It is difficult to establish a
clear relation between the high levels of PRL and trigger-
ing headache attacks. One hypothesis is that PRL could
contribute to the development of certain pain disorders,
possibly including neuro-modulation processing of senso-
ry neurons in the trigeminal ganglia [21]. Indeed it is doc-
umented that receptors of PRL are also situated in trigem-
inal ganglia in rats [22]. Moreover, as the increased secre-
tion of PRL after the TRH test is not linked to pain, we
suppose the occurrence of a PRL critical value above
which headache attacks occur. Nevertheless, a larger num-
ber of patients would be necessary to confirm this hypoth-
esis. Therefore in this case even sleep could play a role in
the manifestation of the attacks. A temporal connection
between attacks and REM sleep has also been suggested,
but no formal data are available to correlate the attacks
with REM or other stages of sleep. It has been shown that
serum PRL levels tend to rise with the cessation of REM
and they are higher during non-REM sleep [23]. In our
case, the attacks occur with variable frequency and
polysomnographic studies showed these attacks occurred
during all sleep stages, including REM sleep. There was a
clear temporal relation between headache attacks and
REM in only 8 out of 42 attacks. As the headache and
amenorrhoea were almost coincident in our patient and
considering that medical treatment of the prolactinoma led
to a resolution in headache symptoms, this strongly indi-
cates that the hyperprolactinaemia plays a central role in
triggering the headache, rather than being a coincidental
pathology. We propose that nocturnal PRL levels should
be evaluated in all patients who suffer from nocturnal
SUNCT attacks, even in the presence of average basal val-
ues or normal PRL values after TRH test. In addition, a
larger screening of patients with SUNCT by basal hor-
mone measurements could be useful, including LH, FSH,
oestradiol, progesterone, T3, T4, TSH, cortisol, ACTH,
testosterone and GH. The possible influence of altered
regulation of PRL, of sleep, of serotoninergic and
dopaminergic mechanism, and the influence and interac-
tions of all the hormones would provide further clarity.
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